Is NCT01653470 results overdue?

Yes — results are overdue. Primary completion was 2017-05-03; the FDAAA-801 reporting deadline (2018-05-03) passed 2971 days ago and no results are posted on ClinicalTrials.gov.

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

NCT ID	NCT01653470 ↗
Sponsor	Bristol-Myers Squibb (INDUSTRY)
Public issuer	BRISTOL MYERS SQUIBB CO — BMY (CIK 0000014272) best-effort name match, 95% conf — verify on EDGAR ↗
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-05-03 (ACTUAL)
Reporting deadline	2018-05-03 (completion + 365d)
Days overdue	2971
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `96fa5d895c549f4b…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01653470. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.